


**TGF- $\beta$ -mediated epithelial-mesenchymal transition of keratinocytes promotes fibrosis in secondary lymphedema.**

**Supplementary data:**

	<b>Value</b>
Patients (n)	4
Age (years)	60.2 $\pm$ 8.3
Baseline BMI (Kg/mg <sup>2</sup> )	24.1 $\pm$ 3.6
ISL stage	
Stage I	1
Stage II	3
Volume differential (%)	13.4 $\pm$ 0.05
Volume differential (cc)	245.7 $\pm$ 95.7
L-Dex Score	19.4 $\pm$ 7.7
Dutation (months)	90.7 $\pm$ 92.7
Radiation (n)	4/4 (100%)
Cellulitis episode/year	6.5 $\pm$ 7.2


**Supplementary table 1.** Demographics of RNAseq analysis performed patients (n=4). Data are presented as mean  $\pm$  standard deviation unless noted. BMI, body mass index; ISL, International Society of Lymphology.



**Supplementary Figure 1. Absence of EMT markers in control mouse tail skin.**

Immunofluorescent images (scale bar, 100  $\mu$ m) of control mouse tail skin harvested 6 weeks post-surgery. Staining shows vimentin (green) along with EMT markers and the basement membrane marker collagen IV (red). Dashed lines delineate the epidermis and dermis. Note the

lack of vimentin<sup>+</sup> cells within the epidermis and the minimal co-expression of vimentin with EMT markers.




**Supplementary Figure 2. YFP<sup>+</sup> cells in lymphedematous dermis express fibroblast**

**markers.** Flow cytometry analysis of isolated dermal cells from control and lymphedematous

mouse tail skin. Top: Quantification of CD90<sup>+</sup> and CD140α<sup>+</sup> fibroblasts in YFP<sup>+</sup> cell populations.

Bottom: Mean fluorescence intensity (MFI) of vimentin and CD26 in YFP<sup>+</sup> dermal cells. \* $p < 0.05$

and \*\*\*\* $p < 0.0001$  by unpaired Student's *t* test.



**Supplementary Figure 3. Lymph fluid from BCRL patients contains TGF-β.** ELISA quantification of TGF-β in lymph fluid from patients with unilateral BCRL.